BMY•benzinga•
U.S. FDA Approves Bristol Myers Squibb's Camzyos™ (mavacamten) for the Treatment of Adults With obstructive HCM
Summary
Bristol Myers Squibb (NYSE: BMY) announced the U.S.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 29, 2022 by benzinga